08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

Akesis endocrine news

Akesis will file for Chapter 7 bankruptcy after discontinuing development of AKP-020, its sole clinical program. The vanadium insulin-enhancer was in Phase IIa testing to treat Type II diabetes. The company said a review of...
07:00 , Oct 16, 2008 |  BC Innovations  |  Cover Story

Spiking diabetes

U.S. and Australian researchers have unraveled a mechanism that could explain the correlation between transient spikes in glucose levels and an increased risk for cardiovascular complications in diabetes patients. 1 The findings could change the...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Akesis scientific advisory board update

Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Business: Endocrine   Appointed: Christos Mantzoros, associate professor of medicine at Harvard Medical School and associate professor in the department of environmental health at the Harvard School...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

Akesis management update

Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Business: Endocrine   Hired: Carl LeBel, a director, as president and COO, formerly executive director for program management and strategic operations at Amgen Inc. ; he replaces...
07:00 , Jul 7, 2008 |  BioCentury  |  Finance

1H08 warrant coverage

1H08 warrant coverage...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Additional Phase IIa data

Data from 9 patients in a Phase IIa trial showed that AKP-020 significantly reduced fasting plasma glucose (FPG) levels from baseline (p<0.05) and nonsignificantly reduced FPG levels vs. placebo. Seven patients received 20 mg of...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Completed Phase IIa enrollment

Akesis completed enrollment of 10 patients in a single-blind Phase IIa trial comparing 20 mg of oral AKP-020 with placebo. The company had originally planned to enroll 21 patients but decided to stop early to...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Preliminary Phase IIa data

Preliminary data from a single-blind Phase IIa trial in the first four patients showed that treatment with AKP-020 reduced plasma glucose levels in the fasted state and two hours after an OGTT vs. placebo. For...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

AKP-020: Phase IIa started

Akesis began a single-blind, placebo-controlled, U.S. Phase IIa trial in 21 patients. The company licensed exclusive rights to AKP-020 from the University of British Columbia. Akesis Pharmaceuticals Inc. (OTCBB:AKES), La Jolla, Calif.   Product: AKP-020...
08:00 , Feb 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Encysive...